C-terminal binding protein 1 (CtBP1) is a transcriptional co-repressor and metabolic sensory protein, which often represses tumor suppressor genes. Hence, we sought to determine if CtBP1 affects expression of the tumor suppressor Brca1 in head and neck tissue, as downregulation of Brca1 begins at the early stages of head and neck squamous cell carcinomas (HNSCCs). We found that CtBP1 represses Brca1 transcription by binding to the E2F4 site of the Brca1 promoter. Additionally, the recruitment of CtBP1 to the Brca1 promoter is redoxdependent, that is, increased at high NADH levels in hypoxic conditions. Further, immunostaining using a human HNSCC tissue array revealed that nuclear CtBP1 staining began to accumulate in hyperplasic lesions and HNSCCs, this staining correlated with Brca1 downregulation in these lesions. Pharmacological disruption of CtBP1 binding to Brca1 promoter by the antioxidant Tempol, which reduces NADH levels, relieved CtBP1-mediated repression of Brca1, leading to increased DNA repair in HNSCC cells. As tumor cells are generally hypoxic with increased NADH levels, the dynamic control of Brca1 by a 'metabolic switch' found in this study not only provides an important link between tumor metabolism and tumor suppressor expression but also suggests a potential chemo preventative or therapeutic strategy for HNSCC by blocking NADH-dependent CtBP1 activity at early stages of HNSCC carcinogenesis. 
C-terminal binding protein 1 (CtBP1) is a transcriptional co-repressor and metabolic sensory protein, which often represses tumor suppressor genes. Hence, we sought to determine if CtBP1 affects expression of the tumor suppressor Brca1 in head and neck tissue, as downregulation of Brca1 begins at the early stages of head and neck squamous cell carcinomas (HNSCCs). We found that CtBP1 represses Brca1 transcription by binding to the E2F4 site of the Brca1 promoter. Additionally, the recruitment of CtBP1 to the Brca1 promoter is redoxdependent, that is, increased at high NADH levels in hypoxic conditions. Further, immunostaining using a human HNSCC tissue array revealed that nuclear CtBP1 staining began to accumulate in hyperplasic lesions and HNSCCs, this staining correlated with Brca1 downregulation in these lesions. Pharmacological disruption of CtBP1 binding to Brca1 promoter by the antioxidant Tempol, which reduces NADH levels, relieved CtBP1-mediated repression of Brca1, leading to increased DNA repair in HNSCC cells. As tumor cells are generally hypoxic with increased NADH levels, the dynamic control of Brca1 by a 'metabolic switch' found in this study not only provides an important link between tumor metabolism and tumor suppressor expression but also suggests a potential chemo preventative or therapeutic strategy for HNSCC by blocking NADH-dependent CtBP1 activity at early stages of HNSCC carcinogenesis. Oncogene (2010) 29, 6603-6608; doi:10.1038 /onc.2010 ; published online 6 September 2010
Keywords: Brca1; CtBP1; NADH; transcription; tumor suppressor; HNSCC Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide (Hunter et al., 2005) . Despite advances in cancer biology and therapy, the 5-year survival for patients with HNSCC has remained 50% for the past 20 years (Forastiere et al., 2001) . To date, the best-studied germline mutations leading to increased HNSCC susceptibility are in genes belonging to the Fanconi anemia/Brca (Fanc/Brca) pathway (Kutler et al., 2003) . Patients with germline mutations in Fanc/Brca pathway genes have a high incidence of HNSCC at a young age (Kutler et al., 2003) . Among Fanc/Brca family genes, some are frequently mutated whereas others are downregulated in sporadic HNSCC (Marsit et al., 2004; Sparano et al., 2006; Weber et al., 2007; Wreesmann et al., 2007) . Mice with epithelia-specific heterozygous knockout of Brca1 developed HNSCCs, indicating that Brca1 loss has an important role in HNSCC tumorigenesis (Berton et al., 2003) . Cells with absent or mutated alleles of Brca1 show many characteristic features of reduced genome stability, including impaired cell cycle checkpoints, reduced efficiency in homologous recombination and defective DNA repair following genotoxic insults (Shen et al., 1998) . Recently we found that a reduction in Brca1 protein occurs frequently in HNSCCs (Bornstein et al., 2009) . As mutations or promoter hypermethylation of Brca1 was detected in only a small fraction of HNSCC patients (Marsit et al., 2004; Sparano et al., 2006) , Brca1 downregulation could occur at the transcriptional or post-transcriptional level in HNSCC. In fact, the Brca1 promoter is controlled by a complex and dynamic array of DNA-binding proteins, transcriptional co-activators and co-repressors (Thakur and Croce, 1999; Atlas et al., 2001; Baker et al., 2003; Mueller and Roskelley, 2003; Bindra et al., 2005; Bindra and Glazer, 2006; De Siervi et al., 2010) . In search for potential Brca1 promoter repression, in this study, we examined the effect of C-terminal binding protein 1 (CtBP1) on Brca1 transcription. CtBP1 was initially recognized as an adenoviral E1A-binding protein and its overactivation, in combination with a mutant Ras, leads to tumorigenesis and metastasis, suggesting that CtBP1 has a critical role in oncogenesis (Subramanian et al., 1989; Boyd et al., 1993; Schaeper et al., 1995; Grooteclaes and Frisch, 2000) . The underlying molecular mechanisms of CtBP1 in oncogenesis could be linked to its function as a transcriptional co-repressor of multiple tumor suppressors, including PTEN, p16 INK4a and p15INK4b (Chinnadurai, 2009) .
We examined CtBP1 protein levels in normal and cancer keratinocytes, respectively ( Figure 1a) . By western blotting, we found that CtBP1 protein levels in normal human keratinocyte HaCaT cells (Gift from Dr Petra Boukamp) were about one-third of that in Fadu cells, an HNSCC cell line from a human hypopharyngeal carcinoma (from ATCC). After knocking down CtBP1 expression in Fadu cells using a CtBP1 specific small interference RNA (Zhang et al., 2003) , we measured Brca1 mRNA by quantitative real time-PCR; Brca1 mRNA levels increased threefold (Figure 1b) . Consistently, the increased Brca1 protein level correlated with the reduced CtBP1 protein level in siCtBP1 transfected Fadu cells (Figure 1c ). These data suggest that CtBP1 downregulates Brca1 expression in HNSCC cells.
CtBP1 serves a key role in cellular regulation by binding to a variety of transcriptional repressors critical for development and tumorigenesis (Chinnadurai, 2002) . Therefore, we assessed whether CtBP1 was recruited to the Brca1 gene to repress transcription. We performed chromatin immunoprecipitation (ChIP) to identify the CtBP1 binding sites at the Brca1 promoter region in Fadu cells, using an antibody against CtBP1 (Millipore, Billerica, MA, USA) ( Figure 1d ). As CtBP1 typically binds near the transcriptional start site at promoters (Zhang et al., 2006 Kim and Youn, 2009) , we searched for possible binding sites in the Brca1 promoter regions within À1.3 to þ 1.1 kb of the transcriptional start site. PCR primer sets encompassing the above regions were used in quantitative-PCR of ChIP DNA to identify CtBP1 binding sites, and ChIP using a normal IgG (Jackson Immuno Research, West Grove, PA, USA) was used as a negative control (Figure 1d ). A CtBP1 binding site was found surrounding the transcriptional start site of the Brca1 promoter. CtBP1 binding was confirmed by an independent ChIP using a different anti-CtBP1 antibody (Santa Cruz, Santa Cruz, CA, USA) (data not shown). To examine if this CtBP1 binding site confers transcriptional repression to the Brca1 gene, we constructed a firefly luciferase (Zhang et al., 2003) . Cells were immediately transferred to 0.5 ml DMEM with serum and incubated at 37 1C for 48 h. Total RNA was isolated using TRIzol (Invitrogen) and qRT-PCR was performed as previously described (Zhang et al., 2006 ). An 18S probe was used as an internal control. The relative RNA expression levels were determined by normalizing with internal controls, values were calculated using the comparative Ct method. Samples were assayed in triplicate for each experiment and at least two independent experiments were performed. Data are presented as mean ± s.e.m. from a representative experiment. (c) CtBP1 knockdown increases Brca1 protein in Fadu cells. Fadu, a human HNSCC cell line with a high CtBP1 level, was transfected with scrambled siRNA (Control) or siRNA to CtBP1 (siCtBP1) and its CtBP1 and Brca1 protein levels were measured by western blotting using antibodies from Santa Cruz. Tubulin was used as a loading control and molecular markers are labeled. (d) CtBP1 binding to the Brca1 regulatory element. Fadu cells were used for ChIP assay with an anti-CtBP1 antibody as described previously (Zhang et al., 2006) . Primer sets encompassing À1.3 to þ 1.1 kb of the Brca1 promoter were used to q-PCR-amplify the ChIP sample. *Po0.05 vs IgG. (e) CtBP1 represses Brca1 reporter, as siCtBP1 relieves repression of Brca1 reporter. The pGL4.26 Brca1 promoter luciferase reporter plasmid was generated by cloning a PCR-amplified 700 bp fragment of the Brca1 promoter spanning the TSS into the KpnI and BglII sites of pGL4.26 vector (Promega). Brca1 promoterspecific primers used were 5 0 -ggggtaccGACCTCTTCTTACGACTG-3 0 (forward) and 5 0 -gaagatctTTCCTGATCCTCAGCGC-3 0 (reverse). An empty renilla luciferase vector (pGL4.79) was use for normalization. Fadu cells were transfected with scrambled siRNA (Control) or siRNA to CtBP1 (siCtBP1) and the luciferase activity was measured (Zhang et al., 2002) . (f) CtBP1 bound to E2F4 at the Brca1 promoter. Sequential ChIP using an anti-E2F4 antibody (Santa Cruz) followed by a CtBP1 antibody (Millipore) was performed in Fadu cells; Po0.02 vs second ChIP using IgG. Primers surrounding the proximal promoter region of Brca1 were used to PCR-amplify the ChIP sample. (Figure 1e ). As a co-repressor, CtBP1 has been found in corepressor complexes containing the CtBP1 binding adaptor protein CtIP and transcription factor E2F4 (Meloni et al., 1999) . Therefore, we searched potential transcription factor binding sites around the above CtBP1 binding site, and found that E2F4 has been reported to bind in this region of the Brca1 promoter (Bindra and Glazer, 2006) . We performed sequential ChIP using an antibody against E2F4 (Santa Cruz) for the first ChIP and an antibody against CtBP1 (Millipore) in the second ChIP. CtBP1 co-existed with E2F4 on the Brca1 promoter (Figure 1f) .
To further assess if restoration of Brca1 expression by CtBP1 knockdown in Fadu cells attenuates loss of Brca1-mediated DNA repair foci formation, we examined Brca1-mediated DNA repair foci formation by immunofluorescence staining using the Fadu and FadusiCtBP1 cells treated with mitomycin C (MMC, Sigma, St Louis, MO, USA). Under normal conditions, Brca1 translocates to sites of MMC-induced DNA damage with other members of the Fanc/Brca pathway to form DNA repair nuclear foci (D'Andrea and Grompe, 2003) . 24 h after 10 ng/ml MMC treatment, only about 10% of Fadu cells were able to form Brca1 foci, whereas Fadu cells with siCtBP1 added 48 h before MMC treatment (that is, 72 h of CtBP1 knockdown) exhibited a threefold increase in the number of cells able to form MMC-induced DNA repair foci, from 13.5 ± 1.3 to 42.2±2.9 per 100 cells (Po0.01) (Figure 2a) . Furthermore, foci-formation using a Rad51 antibody also revealed that the number of foci changed from 5.6±3.0 to 17.5±3.7 per 100 cells after CtBP1 knockdown (Po0.02) (Figure 2a ). These data suggest that CtBP1-mediated Brca1 repression abrogates Brca1 function.
Different from other transcriptional co-repressors, CtBP1 protein is uniquely structured to sense changes in free nuclear NADH concentration (Zhang et al., 2002; Fjeld et al., 2003) . Studies by us and others have demonstrated that changes in cellular redox potential alter the interaction of CtBP1 with DNA-binding transcription repressors (Zhang et al., 2002 (Zhang et al., , 2006 Barnes et al., 2003; Mirnezami et al., 2003; Kim et al., 2005; Kim and Youn, 2009) . Therefore, as a 'foe' of multiple tumor suppressors, CtBP1 also provides a link between transcriptional regulation and the metabolic status of the cells. This link is especially important given the high NADH concentration associated with hypoxia and the glycolytic nature of solid tumors. To investigate whether CtBP1-mediated repression of Brca1 gene is sensitive to NADH levels, we used ChIP assays to examine CtBP1 occupancy on the Brca1 promoter under hypoxic condition. Our previous study has shown that hypoxia increases free cellular NADH levels, which affects CtBP1 activity without affecting its levels (Zhang et al., 2002 (Zhang et al., , 2006 . Consequently, Fadu cells exposed to hypoxia (1% O 2 for 3 h) showed a 2.5 fold increase in CtBP1 recruitment to the proximal region of Brca1 promoter (Figure 2b ). Consistent with CtBP1 binding, Brca1 mRNA levels were reduced in hypoxia (Figure 2c ). To further determine if hypoxiamediated Brca1 reduction depends on endogenous CtBP1, we knocked down CtBP1 in Fadu cells with hypoxia treatment. Small interference RNA knockdown of CtBP1 largely attenuated the repressive effect of hypoxia on Brca1 transcription (Figure 2c) . Therefore, recruitment of CtBP1 to repress Brca1 gene transcription clearly depends on NADH level. Brca1 transcription has been shown to be regulated by various environmental stimuli (Andres et al., 1998; Bindra Siervi et al., 2010) . Our study demonstrates the unique redox regulation of Brca1 transcription through the NADH sensor CtBP1. CtBP1's recruitment to the Brca1 promoter is upregulated by hypoxia, supporting the proposed role of hypoxia and anaerobic glycolysis in promoting tumor formation through the downregulation of tumor suppressors including Brca1.
Our data suggest that under normal conditions, Brca1 expression in keratinocytes is not repressed by CtBP1 because of low levels of CtBP1 and NADH. However, during HNSCC carcinogenesis, increased levels of CtBP1 and NADH facilitate CtBP1-mediated repression of Brca1. To determine at which stage CtBP1 begins to be overexpressed in vivo during HNSCC carcinogenesis, we used immunohistochemistry to examine CtBP1 expression on an HNSCC-tissue array containing HNSCCs, hyperplastic mucosal tissues and non-cancer controls (US Biomax, Rockville, MD, USA). Among 20 cases of hyperplastic lesions and 54 cases of HNSCCs, we found nuclear CtBP1 staining in 45% hyperplastic lesions and 80% HNSCCs (Table 1 and Figure 3) but not in non-cancer head and neck tissues (data not shown). As we previously reported (Bornstein et al., 2009) , downregulation of Brca1 began in hyperplastic lesions of HNSCC patients (Table 1 and Figure 3 ). Interestingly, CtBP1 nuclear staining correlated with Brca1 downregulation in hyperplastic and HNSCC cases (Table 1 and Figure 3 ). These data strongly support CtBP1 repression of Brca1 expression in vivo. Further, our data suggest that CtBP1 upregulation begins in the early stages of HNSCC carcinogenesis; hence blocking CtBP1 activity could be a potential chemopreventive approach. Tempol, an antioxidant exhibiting a chemoprevention effect in several studies (Mitchell et al., 2003; Schubert et al., 2004; Erker et al., 2005; Zhang et al., 2008) and functioning as a topical radioprotector in a Phase I clinical study (Metz et al., 2004) , is a stable free radical that downregulates NADH by converting nitroxide to the corresponding hydroxylamine (Iannone et al., 1990; Krishna et al., 1992) . Therefore, we investigated whether CtBP1 repression of Brca1 can be relieved by Tempol. As free cellular NADH/NAD ¼ 1/700, the conversion of NAD to NADH mainly affects the free cellular NADH level, that is, the decreased cellular NADH/NAD ratio measured by lactate/pyruvate ratio (L/P ratio) indicates a decrease in free NADH concentration (Williamson et al., 1967) . Treating Fadu cells with 0.1 mM Tempol (Sigma) for 16 h caused a threefold decrease of cellular NADH level (Figure 4a) . Concomitantly, CtBP1 recruitment to the Brca1 promoter was decreased (Figure 4c) , even though CtBP1 level and localization remained unchanged during the Tempol treatment (Figure 4b) . Consequently, Brca1 expression was increased by Tempol treatment of HNSCC Fadu cells (Figure 4d ). Quantitative real time-PCR assay showed 
% of Brca1 downregulation in CtBP1 ( þ ) or (À) cases Hyperplastic Mucosa 5/9 (55.5%)* 0/11 (0%) HNSCC 37/43 (86%)** 3/11 (27%) *Po0.01; **Po0.001, between CtBP1 ( þ ) and CtBP1 (À) groups. Figure 3 Correlation between CtBP1 upregulation and Brca1 downregulation in a human HNSCC tissue array (US Biomax HN801). Immunohistochemical staining was performed using antibodies against Brca1 (Santa Cruz) and CtBP1 (Millipore) to stain consecutive tissue sections as we previously described (Bornstein et al., 2009) . Sections were counterstained with hematoxylin. Evaluation of CtBP1 and Brca1 staining of human HNSCC samples was performed by two independent investigators using methods described previously (Bornstein et al., 2009) . Note that a hyperplastic lesion with CtBP1 nuclear staining (a) showed negative staining for Brca1 in the consecutive section (b). In contrast, a hyperplastic lesion with CtBP1 staining in the cytoplasm but little in the nucleus (c) exhibited positive Brca1 staining (d). The same correlation was also observed in HNSCC lesions, in which predominant nuclear CtBP1 staining in (e) barely had Brca1 staining in (f). In contrast, in section (g), tumor epithelial cells showed either cytoplasmic CtBP1 staining (upper areas) or no CtBP1 staining (lower areas); the consecutive section in (h) showed positive Brca1 staining. The scale bar in the first panel represents 40 mm for panels a-f and 80 mm for panels g, h.
Tempol stimulates Brca1 transcription by blocking CtBP1 Y Deng et al that Brca1 mRNA levels in Fadu cells increased three-fourfold by Tempol treatment. As Tempol is an anti-oxidant, its effect on Brca1 expression may be contributed from its effect on NADH and/or anti-oxidant effects. To determine the contribution of NADH levels to the effect of Tempol, we induced hypoxia in Tempol-treated cells and examined Brca1 levels. Hypoxia treatment largely attenuated the effect of Tempol on Brca1 expression ( Figure 4d ). As oxidation is suppressed during acute hypoxia (Wu et al., 2007) In summary, our current analysis revealed a direct transcriptional repression of CtBP1 on Brca1 expression in head and neck epithelial cells, which is also dependent on cellular NADH levels. We also report that CtBP1 is overexpressed in human HNSCC and it's overexpression correlated with Brca1 downregulation. The unique NADH-dependence of CtBP1's action not only highlights the importance of hypoxia and anaerobic glycolysis in promoting tumor formation through activation of CtBP1, but also reveals a potential chemo-preventative/therapeutic approach for HNSCC, which warrants future studies to test this approach in HNSCC animal models before clinical trials. It will be interesting to explore if the mechanism of Tempol action found in this study can be applied to other anti-oxidants for their chemoprevention effects. Moreover, as Brca1 is a tumor suppressor in multiple organs/tissues, it will be interesting to assess if CtBP1-mediated Brca1 repression contributes to cancer in multiple cancer types as the chemoprevention potential suggested by our current study could have broader applications. (Williamson et al., 1967) . As free NAD is in greater excess than free NADH, the conversion of NAD to NADH mainly affects NADH level. Therefore, the L/P ratio indicates the free NADH level (Williamson et al., 1967) 
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